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Microbubble drug delivery systems vary widely in their design and. This work focused on the 
application of a novel microbubble system with ultrasound-mediated delivery enhancement via 
consumer equipment.  
The work involved the creation of a novel microbubble formulation using a prodrug of Bexarotene 
to make the exterior layer of the microbubble. This started with development and engineering of 
productions schemes for stable microbubbles. Physical characterization was done to confirm 
production and was followed by initial in vitro testing. Results were indicative that microbubbles 
were formed via the protocol developed, and phantom imaging studies confirmed the enhance 
contrast from microbubbles for ultrasound imaging. Additionally, the in vitro tests showed 
enhance effectiveness in drug delivery for C32 cells through multiple assays. Demonstrating the 
effectiveness of using lipid type prodrugs for the creation of microbubbles and their uses for 
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Drug delivery is delivering unadulterated drug molecules to damaged tissue sites for therapeutic 
purposes. This encompasses many aspects, from the drug itself to how it was being administered. 
Throughout the modern era of drug delivery, the goals have continuously been changing. In the 
past at the beginning of the field, drug delivery technology was engineering slow release capsules.  
With the advent of nanotechnology liposomal formulations were developed [1-3]. 
Functionalization could be done on their surfaces, allowing for highly specific delivery with a 
higher payload of drug and circulation time within the body. There have been numerous attempts 
to make nanoparticles out of materials from simple carbon to heavy metals to allow for multiple 
benefits such as imaging or diagnosis [4-6]. Additionally, there has been some effort to use micron-
sized bubbles for theranostic applications adapting them from the previous role as an imaging 
agent [7]. This was the focus of the work described in this thesis. 
The development of microbubbles for medical diagnosis can be traced back to 1968, where they 
were first used as an imaging agent to enhance contrast within circulating tissue for ultrasound 
imaging [8]. The characteristic that allows for this enhanced imaging involves the physical 
interaction between the material and gas of the microbubble and the ultrasonic waves. As the 
ultrasonic waves interact with the bubble it will expand and contract. This changes the tissue 
attenuation leading to enhanced contrast on the image when it is reconstructed [9, 10]. This 
principle also causes the bubbles to continually flex until the bubble breaks. When the bubble 
breaks it leads to a cavitation event on the micro scale, and when attached to the cell it can create 
a jet stream into the cell membrane [11,15]. Exploiting this aspect was the focus of this work using 
ultrasound and their interaction with microbubbles to enhance drug delivery. The bubbles 
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themselves can be made from a variety of materials such as lipids, proteins, and polymers. Each 
having its own set of benefits and drawbacks, but one common aspect was that they all at their 
core use a medically compatible gas. Originally common medical gases were used like oxygen and 
nitrogen, but as research progressed they fell out of favor for heavier gases that were less 
susceptible to liquid diffusion such as octofluoropropane and other halocarbons [12].  
In our approach, the microbubble surfactant shell that was entirely made from prodrug followed 
by exposure to ultrasound from a consumer product described in Chapter 2/3. Normally the 
therapeutic molecules were located in the core or attached to the surface of the microbubble [13, 
14]. These microbubbles use a lipid-based prodrug to make the entire shell of the bubble. This 
allows for a higher loading and in conjunction with ultrasound exposure for a lower overall in vitro 
concentration for similar effects.  
Designing of the bubble started first with the creation of a stable prodrug, and this was adapted 
from Misra et al. to create a prodrug of Bexarotene [15]. Then the creation of a protocol for stable 
microbubbles was attempted utilizing inert soy lecithin and octofluoropropane gas. Various 
parameters were established through experimentation such as sonication time, lipid melting 
temperatures, lipid concentration, solvent usage, sonication set up. This was done to attempt to 
create stable microbubbles. There were multiple optimization steps at the formulation and the 
following in vitro work. The basis of microbubble creation was based on work from McEwan et 
al. [16]. After the formulation was optimized it was followed up with in vitro testing using a 1MHz 







Lysophosphatidylcholine (LysoPC) was used as the single tail lipid for drug conjugation and was 
obtained from Avanti Polar Lipids (Alabaster, AL). Bexarotene was used as the therapeutic 
molecule and was purchased from AKscientific (Union City, CA). 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC), Anhydrous Chloroform at 99% purity, and catalytic 
Methylpyridine were purchased from Sigma Aldrich (St. Louis, MO). The ultrasound machine was 
a USPro TENS 2000 that produced ultrasonic waves at 1.5   and 1 MHz. It was bought through 
TENSPro (St. Louis, MO). Ultrasonic coupling gel was purchased through Amazon (Seattle, WA) 
and was branded Electrogel. Octofluoropropane (OFP) was purchased from Electronic 
Fluorocarbons Inc, (Hopkinton, MA) at 98% purity. Dialysis cassettes at a molecular weight cutoff 
at 10000 kDa were bought from Thermo Fisher Scientific (Waltham, MA). MEM media was used 
in conjunction with sodium pyruvate and essential amino acids to create EMEM and were bought 
from Corning Life Sciences (Corning, NY). Soy Lecithin (HSPC) was purchased from NOF 
America (White Plains, NY). PCR film was purchased from Thermo Fischer Scientific (Waltham, 







2.2 SYNTHESIS OF PRO-BEXAROTENE 
The synthesis of Pro-Bexarotene was done by combining reagent followed by mixing for 1-2 days. 
The following reagents were combined in the masses as follows 19.1 mg or LysoPC, 24.5 mg of 
Bexarotene, 14.2 mg of EDC, and a catalytic amount of Methylpyridine. This was then dissolved 
in approximately 1.5 mL of anhydrous chloroform and left to mix for 1-2 days. The extent of the 
reaction was periodically checked using thin layer chromatography (TLC) [15]. As the prodrug 
forms, there was more streaking on the TLC than in the unformed drug. Figure 2.1A shows a 
cartoon diagram of a developed TLC plate. The progress of the reaction where there was a clear 
streaking section in the Pro-Bexarotene indicated a larger more polar product formed. This was 
then followed up by mass spectrometry to confirm a molecule of 826  was formed indicating 
drug formation. Figure 2.1B shows the elemental report from the Mass spectroscopy facilities. 
After confirmation, the solution was washed in a workup with a minimal amount of water to 
remove the catalyst, and the prodrug/chloroform layer was collected into a 20 mL scintillation vial. 
The solvent was then evaporated in the rotary evaporator using a rubber septum and syringe needle 
to discourage condensation of chloroform. Then it was followed up with vacuum pump desiccation 
for 4-6 hours to ensure all chloroform has been removed from the drug. The product was then 
massed and sealed with parafilm and kept at 4 ⁰C. The resulting material was off-white and slightly 






Figure 2.1: Displays the analytical results of the prodrug reaction. (A) Shows a cartoon of a TLC 
plate for showing Pro-Bexarotene formation in the streak at 2.2 cm. (B) Shows the results of the 
mass spectrometry post purification with a clear peak at 826 m/z indicative of the prodrug. 
2.3 MASS SPECTROMETRY 
Mass spectrometry was conducted on samples to confirm successful production of Pro-
Bexarotene. Samples were submitted to the University of Illinois School of Chemical Sciences 
Mass Spectrometry Laboratory. The machine used was a Waters Q-TOF Ultima ESI (Waters 
Corporation, Milford, MA), the sensor had a FWHM of 1000V and was used for smaller molecules 
and peptides (<10000 Da). High-resolution electrospray ionization was utilized by the machine to 
provide an accurate representation of the elements and compounds present in the product. The 
samples were prepared by dissolving 1 mg of the product into 1 mL of anhydrous chloroform, and 
by pipetting a small sample of the mixing reagents into 0.5 mL of anhydrous chloroform. The 




2.4 SHAKING MICROBUBBLE FORMATION  
Microbubbles were formed in two distinct techniques before selecting the optimal method for in 
vitro testing. The first option explored was shaking and the second option was a two-step 
sonication. The shaking method required creating a film of lipid, melting said film, and shaking 
vigorously under a sealed octofluoropropane environment. This was started by dissolving a 
selected amount of lipid in chloroform, in the original tests it was soy lecithin was chosen and 5 
mg was dissolved in 1 mL of anhydrous chloroform. This was then placed in a rotary evaporator 
and spun at 40 ⁰C under vacuum. After all the chloroform has evaporated the film was dried 
overnight in a vacuum desiccator. The next step was adding the solvent Dulbecco’s Phosphate-
Buffered Saline (DPBS). Followed by stirring and heating at 60 ⁰C and 200 rpm for 20 minutes. 
Then the stir bar was removed, and a septum was placed to seal the liquid. Octofluoropropane 
replaced the air inside the by using a two-needle system as gas was released inside of the vial an 
open needle was also placed in the septum to allow for air/gas to escape. The octofluoropropane 
was released from the cylinder at 0.3 psi for 15 seconds followed by removal of the open needle. 
The gas needle then was placed into the liquid and when bubbles exiting the needle stop the vial 
was saturated. This was approximately 15 seconds with the same pressure. The vial was then sealed 
with parafilm and secured to a ThermoFisher MaxQ 2000 high-speed rotary shaker (Thermo 







2.5 SONICATION MICROBUBBLE FORMATION 
The steps to form microbubbles via sonication are summarized as followed formation of a lipid 
film, homogenization of said film, and sonication under gaseous headspace. First, the lipid was 
measured in a 20 mL scintillation vial the mass was recorded, and then dissolved in approximately 
1 mL of anhydrous chloroform. The liquid was then evaporated in a rotary evaporator at 40 ⁰C. 
Following evaporation, the vial was opened and placed in a vacuum desiccator overnight to further 
dry and create the solid film. The film was hydrated the next day to create a sample that was 1  
using DPBS as the solvent. This was then stirred and heated covered on a hot plate for 20 minutes 
at 60 ⁰C and 200 rpms. The stir bar was removed followed by the first sonication process. Where 
Qsonica Probe Sonicator Model Q700 (Qsonica, Newtown, CT) with  inch sonic horn was used 
homogenize the solution and fully disperse the lipid in the liquid. The settings were set at a power 
amplitude of 4 for 30 seconds with all the time designated on time. The sonication horn was passed 
over the entire base to make sure that all excess lipid was freed from the glass. The solution can 
then be placed in the dialysis cassettes and using nanopure water with a stir plate at 150 rpms this 
was done for 3 hours. After which the solution inside the cassette was transferred to a 50 mL plastic 
conical tube. The tube was placed so the sonication horn was just under the interface of the liquid 
and the air. The settings were changed to a power amplitude of 88 for 15 seconds with all the time 
designated on time. The top of the open tube was sealed with parafilm. Then the octofluoropropane 
was released from the tank with a pressure of 0.3 psi and this punctures the parafilm to flow over 
the liquid for 30 seconds to saturate the space above the liquid. Then the sonication was started 
with the gas continuously flowing over. After sonication was completed the solution was added 
back to a new 20 mL vial and the top was sealed with a septum and parafilm. The air was replaced 
by using the gas needle and another open needle to allow for air to leave. After 15 seconds the 
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open needle was removed, and the gas needle was placed under solution when bubbles stop coming 
out of the needle the solution was saturated and the gas needle can be removed [16, 19]. The cloudy 
solution was the microbubbles.  
2.6 PRO-BEXAROTENE MICROBUBBLE FORMATION 
The sonication method was selected and applied to creating the Pro-Bexarotene microbubbles 
(PBMB). The protocol was simply adapted by changing the lipid from soy lecithin to Pro-
Bexarotene. 
2.7 DLS MEASUREMENTS 
Hydrodynamic diameter distribution was initially used as the basis for size calibration of both 
particles and bubbles. The measurement was done on a Malvern Zetasizer ZS90 (Malvern 
Instruments Ltd, Malvern, UK) using dynamic light scattering at a fixed 90-degree angle. The laser 
in the machine was 400 nm and the photon counter ran around 250 kcps. The measurements were 
autocorrelated and displayed as diameter between 0.001 and 10 µm. The samples were prepared 
by mixing 100 µL of solution with 900 µL of nanopure water in a cuvette. Measurements were 
done in fifteen consecutive measurements and repeated three times. 
2.8 UV-VIS SPECTROSCOPY 
Ultraviolet and visible light absorbance can be used to quantify the amount of drug present in a 
solution through the Beer-Lambert Law [20]. The measurements were done using a GENESYSTM 
10S UV-Vis Spectrophotometer (ThermoScientific, Waltham, MA). Spectra was examined from 
wavelengths of 200-900 nm with acquisitions of data every 1 nm. Samples were diluted drug 
dissolved of a known concentration in the phenol-free media to create a calibration curve. 
Followed by using samples from experiments for quantification.  
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2.9 ACCUSIZER FX 
The Accusizer was used to accurately measure and counts sub-micron to micron-sized particles 
from 0.7 µm to 20 µm in diameter. This technique utilized single particle optical sizing (SPOS) 
where single particles were channeled using the sheath fluid. As the particles moved across the 
laser scattering and extinction sensor, data was measured and then was used with a calibration 
curve to create concentration and size distributions. The machine used was an Accusizer FX 
Particle Sizer (Particle Sizing Sytems Nicomp, Port Richey, FL) and it is housed in the Beckman 
Institute of Advanced Science & Technology (Urbana, IL). The samples were diluted into 15 mL 
sample of DPBS and 1 mL of concentrated solution. This could be used with the data provided to 
measure the concentration of particles formed as well. 
2.10 MTT ASSAY 
To test the efficacy of the microbubble system C32 cancer cells were tested with the treatment and 
a (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT) assay (Sigma-Aldrich, 
MO, USA). MTT solution was prepared by combining (3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) with sterile DPBS to create a concentration of 0.5 M, and 0.22 µm 
syringe filtration. The contents were frozen and wrapped in aluminum foil because of 
photosensitivity. Multiple optimizations of the MTT were required using various plates and 
arrangements these are seen in the Chapter 3.4 MTT Optimization. Since both 96 and 24 well 
plates were used the volumes for both will be described. In 96 well plates (Greiner Cellstar® 96 
well plates, Sigma-Aldrich, MO, USA) cells were seeded with 10,000 cells per well and a volume 
of 200 µL of EMEM media. Similarly, for 24 well plates (Greiner Cellstar® 24 well plates, Sigma-
Aldrich, MO, USA) cells were seeded at a density of 50,000 cells per well in a volume of 0.5 mL 
of EMEM. In the case of both plates, cells were grown for 24 hours until 70-80% confluent. Then 
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prepared for treatment as described in Chapter 2.12 In Vitro Experimentation. Following testing 
the media with the drug was removed after 6 hours of incubation and replaced with a fresh set of 
EMEM depending on the plates. After 24 hours of the treatment, the MTT assay was performed 
by adding the MTT solution to create a 0.45   solution in the media for each well, so for the 96 
well plate 20 µL was added and the 24 well plate 50 µL was added. The plates were placed in an 
incubator for 4 hours. After which the media with MTT solution was aspirated off and replaced 
with an equivalent amount of DMSO (DMSO, ≥99%, MP Biomedicals, USA) to create a violet 
color solution in the wells. These were quantified for optical absorbance using a Synergy HT Plate 
Reader (BioTek, Winnoski, VT) with a reference wavelength of 592 nm. The cell viability was 
calculated using the Equation 1 [21]. 
𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 =
𝐴 ,  − 𝐴 ,
𝐴 ,  − 𝐴 ,
∗ 100 
(1) 
2.11 C32 CELL CULTURE 
C32 melanoma cells were used as a model for the disease. They are an adherent immortal cell line 
sourced from ATCC (Manassas, VA). The cells were grown until the growth phase begins 
followed by plating and testing. Cells were plated in 24 and 96 well plates for in vitro testing. The 
media used for growth was Eagle’s minimum media (EMEM) consists of low levels of glucose 
compared to DMEM. Cells were plated for 1 day prior to testing.  
2.12 IN VITRO EXPERIMENTATION 
In vitro experimentation was done through multiple phases starting with optimization of the 
ultrasound exposure. The ultrasound machine used the continuous frequency application of 1 MHz 
and 1.5  as the power rating. The energy supplied from the machine was able to melt the plastic 
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if held for too long in a single position. So, to test an optimized exposure time cells were plated in 
24 well plates as seen in the Figure 3.9B. After 1 day of plating, the media was removed, and the 
cells were washed with DPBS buffer. The buffer was removed and replaced with new buffer that 
overfills the wells to create a convex dome of liquid. In the case of the 24 well plates used in the 
experiment 3.7 mL of the buffer was used. Then the plate was sealed using the PCR film and all 
the air was removed with a squeegee. The plates were taken to the ultrasound machine where a 
layer of conductive gel was placed on the sites of cells and the plate was inverted and ultrasound 
energy was passed upward through the liquid. These were tested in triplicates over varying times 
of exposure. An optimized time of 2 minutes was found. The same treatment was done for the 
microbubble-based delivery. In this case, the bubbles were they suspended in phenol-free DMEM 
and used for treatment. Quantification of all in vitro experiments was done through MTT assays. 
2.13 BRIGHTFIELD MICROSCOPY 
A Leica DMI3000 B (Leica Microsystems GmbH, Wetzlar, DE) was used to image the 
microbubble formation. Owing to the large size of microbubble they can be visualized through 
light microscopy. 20X magnifications were used to image the bubble. Samples were prepared 
using freshly prepared stocks or samples kept under an octofluoropropane atmosphere. The 
samples were taken from the stock and were dropped using a 23G needle onto a glass slide. A 
glass cover slide was placed on top of the sample prior to imaging. Qimage software with a CCD 






2.14 MICROBUBBLE DISSOLUTION EXPERIMENT 
This experiment was done to assess if the ultrasound machine shown in Figure 2.2 could be used 
to break apart the microbubbles. Control microbubbles were formed using HSPC and the protocol  
Figure 2.2 Image of consumer ultrasound equipment used for experiments.  
from Chapter 2.4. A 24 well plate was utilized as a platform for this experiment where the 900 µL 
of DPBS was added to a well followed by 100 µL of mixed control microbubble solution to the 
well. Followed by sealing and treatment with the ultrasound machine. Samples were exposed for 
1-minute intervals. The full volume of the exposed sample was then transferred into a cuvette and 
measured for size via DLS.  
2.15 FLOW CYTOMETRY 
Flow cytometry was done on in vitro tested cells to assess DNA damage, and Propidium Iodide 
was selected as the stain with an excitation/emission at 538/636 nm. C32 cells were grown to 90% 
confluency and then plated into two 6 well plates at a density of 0.5 ∗ 10  . These were 
arranged to minimize local interaction of treatments from ultrasound exposure utilizing 2 wells 
farthest apart from each other on the plate. There were samples done as control ultrasound, no u 
ultrasound, particles without ultrasound, microbubbles with ultrasound, and microbubbles without 
ultrasound. After samples were treated and incubated like the in vitro testing in Chapter 2.12. 75% 
(v/v) fixing ethanol was chilled in ice at the start of the experiment. The cells were trypsinized 
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from the plates and collected with warmed EMEM media. This was followed up with pelleting by 
spinning at 2500 RPMs for 5 minutes. The supernatant was discarded, and the pellets were washed 
DPBS and transferred into 1.5 mL centrifuge tubes. These were spun at 4000G for 5 minutes. The 
supernatant was discarded, and the pellet was resuspended in the 75% (v/v) fixing ethanol. 
Following resuspension, the ethanol was mildly vortexed to ensure proper suspension of the 
pellets. The samples were then stored overnight at -20 ⁰C. The next day the cells were repelleted 
by spinning at 4000G for 5 minutes and the supernatant was removed. The pellet was washed with 
200 µL of DPBS suspension followed by similar spinning. The washing step was done twice. After 
final wash pellet was resuspended in 400 µL of DPBS and 4 µL of RNase A was added to each 
sample. The samples were sealed with parafilm and incubated at 37 ⁰C for 24 hours. The next day 
the samples were removed and 2 µL of Propidium Iodide was added to each sample and incubated 
in the dark for 30 minutes [23]. After which 600 µL of DPBS was added to each tube and in a 96 
well plate 200 µL aliquots were made allowing for 5 replicates of each experiment. Samples were 
analyzed using a Guava EasyCyte Plus Flow Cytometer (EMD Millipore, Darmstadt, DE). For 
each sample, data from 5000 single cell events were collected for 3 minutes, and in triplicates, at 
red channel having an excitation wavelength of 633 nm. 
2.16 ULTRASOUND IMAGING  
Ultrasound imaging was done using a Siemens Sonoline Antares system (Siemens AG, Erlangen, 
DE). A linear transducer was used at a frequency of 3.5 MHz. The images were reconstructed 
using Siemens software onboard. Samples taken were as followed control microbubbles, Prodrug 
Microbubbles, and water. Phantom was made from a common household straw where one end was 
heated and crimped to seal it. The samples were placed in the solution and attempted to be 
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completely covered in the gel to maximize the image quality. These images were retrieved from 
the system as diacom files and analyzed using ImageJ to quantify contrast improvement.  
2.17 AVOGADRO 
Avogadro is a freeware used for auto optimization for energy minimization of molecules. It was 
developed and distributed by University of Pittsburgh Chemistry Department [24]. Molecules were 
drawn and auto-optimized using a uniform force field around the atoms. The results were displayed 
in Van der Waals spheres. Additionally, the measurement tool was used to estimate the dimensions 
of the various molecules for packing parameter calculations.  
2.18 MATLAB 
MATLAB (Mathworks, Natick, MA) is a matrix-based programing language written in C, C++, 
and Java and was used for numerical simulations of ordinary differential equations. In this work, 
the values of the parameter were taken from Sarkar et al. [30]. Many parameters were kept constant 
as they were indicative of the system being studied. The value of surface tension was estimated 
through tensiometry in Chapter 2.19. The functions and equations were inputted as described by 
Sarkar, et al., and the stiff ODE simulation was run for 100001 number steps for a total time of 
10  seconds. Additionally, using Avogadro estimated values as described in Chapter 2.17 a 
MATLAB script was used to calculate the values. 
2.19 GONIOMETER 
Surface tension was measured through a Rame-Hart Goniometer (Ramé-Hart Instrument Co, 
Succasunna, NJ) at Frederick Seitz Materials Research Laboratory (Urbana, IL). This system used 
a light source and a camera of 1/3” CCD, 100fps, Progressive Scan, Sony Sensor, 659 x 494 pixels 
specifications. Followed by measurement of contact angle through camera measurements. The 
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angle measurement was fitted with the information about the known about the drop area and 
volume the software fits the Young-Laplace equation to estimate surface tension. The samples 
were prepared at the same concentrations used in Chapter 2.4 prior to gas and dialysis. They were 
then measured using the standard aluminum surface and the sessile drop method [25]. 
2.20 STATISTICAL ANALYSIS 
Statistical analysis was done using one and two-way ANOVA with multiple comparisons as well 
using GraphPad Prism software. The treatments were plotted as mean ± standard deviation, and * 




RESULTS AND DISCUSSION 
3.1 DEVELOPMENT AND FORMATION OF MICROBUBBLES 
Prodrug microbubbles were conceptualized using the basis of Misra et al. work in nanobubbles 
which used the same Pro-Bexarotene prodrug for the treatment of liver hematoma [15]. Lipid-
based microbubbles were formed by exploiting the properties of phospholipids where there is lipid 
tail that is hydrophobic and a head that is hydrophilic. As can be seen in Figure 3.1B Pro-
Bexarotene at its optimization forms a similar type of structure. The lipid will arrange into a single 
layer on the surface of the liquids such as water, with the tails facing outward into the air interface 





Figure 3.1 (A) Molecular drawing of Pro-Bexarotene where the cleavable bond can be undone by 
pH or phospholipase activity. (B) Avogadro’s energy minimization of Van der Waals spheres 
representation of Pro-Bexarotene. (C) Cartoon representation of what the microbubble assembly 
with a core of Octofluoropropane (OFP) and a single outer layer of Pro-Bexarotene.  
In the environment the gas of choice was flowed over the interface and through the liquid followed 
by sonication which will cause the bubbles to form of varying size depending on the sonication 
programming shown in Figure 3.1C is a cartoon representation of Pro-Bexarotene Microbubbles. 
Pro-Bexarotene was chosen as the prodrug of choice due to the knowledge of its prior use in a 
bubble assembly. In addition to Bexarotene being an effective therapeutic for melanoma [33]. In 
the following sections, there will sections there will be an explanation on the relation between lipid 




Lipid packing was a key component of micelle self-assembly, and with what was proposed there 
was added a reason to justify why micron-sized bubble may form. Looking at Figure 3.2 it shows 
how phospholipids can be visualized with a hydrophilic head (red oval) and a hydrophobic tail 
(blue cylinder). In a self-assembly, each of these components will arrange in a way such that the 
hydrophobic and hydrophilic components will self-associate. This was where the assembly draws 
stability from the weak interactions that will hold them together. When a gas was introduced it 
attempts to diffuse into the environment, but with tighter packing, this can be reduced [26]. The 
size of the head group was key in determining the what type of assembly will form and in this case 
the bubble. As the head size increases it will favor a spherical micelle and in the case of the prodrug 
as can be seen in Figure 3.2B the optimized conformation of the lipid was similar to a two-tail 







Figure 3.2 Parameter estimation for packing parameter calculations with the estimated values of 
each geometric parameter necessary for the calculation of head surface area, tail volume, and tail 
length (A) Shows the cartoon representation of the Pro-Bexarotene with a large head and sliced 
cone tail shape. (B) Shows the representation of soy lecithin (HSPC) with an extended tail shape.  
for initial testing. This could lead to similar packing in the lipid micelle assembly. Using the 
geometry optimization and measurements of the various molecules from the Avogadro software 
estimated values can be seen in Figure 3.2A/B [24]. HSPC and Pro-Bexarotene had similar 
geometries as seen in A/B. When doing packing parameter calculations these geometries were 
accounted for when solving for equation 2. The packing parameter will indicate the type of 
assembly was likely to form [27]. Where V was the volume of the tail, A was the surface area of 
the head group, and l  was the equivalent length of the phospholipid tail.  
Packing Parameter =    (2) 
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Varying geometries were used to solve for the packing parameter. For HSPC the tail volume was 
taken as a truncated cone (Equation 3). Where r  was the radius of the bottom larger circle, r  was 
the radius of the smaller top circle, and h was the height of the cylinder normal to both circles.  
V = π(r + r r + r )h   (3) 
For Pro-Bexarotene a half-sliced cylinder was used for its volume, and it was calculated by 
constructing a cylinder of a height equivalent to the sum of both side lengths. Then the calculated 
volume of the larger cylinder was halved to provide a volume for Pro-Bexarotene. The surface 
area of both molecules heads was assumed to be ellipsoids, and the uses the modified surface area 
formula Equation 4. This was derived by M. S. Klamskin with modification by Knud Thomsen 
[28]. Where a was half the longest length of the ellipsoid, b was half the length normal to a, c was 
the cross-sectional radius of the ellipsoid at the center, and p was the ellipsoid factor chosen 
between 1<p<2 as described by Klamskin. For this equation p of 1.605 was selected by Knud 
Thomsen due to the ~1.061% error in comparison simulation data [28].  
SA = 4π











Table 3.1: Results of packing parameter calculations using the estimated values and equations for 
both HSPC and Pro-Bexarotene 
Parameter HSPC Pro-Bexarotene 
𝐀 (Å𝟐) 86.197 264.801 
𝐥𝐞 (Å) 17.608 11.322 
𝐕 (Å𝟑) 1511.000 969.322 
Packing Parameter 0.995 0.323 
Associated Shape Flexible Bilayer Spherical Micelle 
Using these equations, values for the packing parameter and components were shown in Table 3.1.  
This was predictive of what the packing will be favored when in gas has been entrapped.  
Optimization & Selection of Protocol 
Starting from the initial protocol from Misra et al. the bubbles were formed using a thin film 
formation where the lipid was dissolved in chloroform following with evaporation to create a layer 
of lipid that when broken up in DPBS with light sonication created micellar structures [15]. Lipid 
layer can disperse and hydrate post sonication through low power probe sonicator pulsing. Using 
the original protocol this would yield micelles on the order of 100-300 nm and similar size bubbles 




Figure 3.3 DLS data of particle and microbubble for the first step in the optimization process. The 
size of both was shown with a large peak at 300 nm with a smaller peak at 4 µm.  
This was expected as the protocol was developed and optimized for nanobubble production. The 
next steps were to examine the key aspects of how to increase the size of the micelles. From 
literature searches, there have been a variety of methods such as microfluidic formation or rapid 
shaking.  






Figure 3.4 Cartoon process diagram to produce microbubble through shaking. Starting with thin 
film formation through the dissolution of lipid in chloroform and rotary evaporation. Followed by 
hydration and replacing air in headspace with OFP and ending with vigorous shaking.  
Experiments were originally conduct using HSPC. The steps for production can be seen in Chapter 
2.4. Using HSPC, the size of bubbles was increased into the micron range with an average 
measured value of 1 µm from DLS. However, when applied to prodrug the bubbles were still 








Figure 3.5 DLS data from shaking method using HSPC and Pro-Bexarotene. Data shows multiple 
peaks for Pro-Bexarotene. With most of the population being below 1 µm, while HSPC shows 
multiple sharp peaks beyond 1 µm allowing for initial confirmation through brightfield 
microscopy. 
The next step in optimization was examining the literature for additional information on 
microbubble formation. Studies done by Borden et al. showed using a similar technique can be 
utilized for microbubble production, and as such, the protocol was the basis of our optimization 
[15]. 
This was worked through using a set up similar to what was described in Misra et al. of creating a 
thin film on glass, followed by melting the lipid in solution and doing a light sonication to 
homogeneously disperse the lipid film. Additionally, a dialysis step in incorporated to remove the 
excessive free lipid/prodrug allowing for a more uniform collection of structures. These were 
measure and due to the high cut off point and varied sonication, the DLS gave a measurement of 
intensity averages in 900 nm. These would be ideal for expansion and creation of microbubbles. 
When applied with the prodrug similar results were seen with number averages in 900 nm. Figure 
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3.6 shows a cartoon of the overall set up of the system.  The constant flow of octofluoropropane 
allows for better yield when  
 
Figure 3.6 Process diagram to produce microbubbles through sonication. Thin film formation 
followed by hydration same as the prior process with the addition of a low and a high sonication 
steps to form microbubbles instead of shaking. This allowed for a more homogenous product when 
tested with HSPC. 
attempting encapsulation compared to shaking where the time for gas incorporation was not nearly 
at the same amount. Effects of oscillatory pressure changes at the surface of the lipid-DPBS 
solution allow for rapid incorporation of the octofluoropropane around the lipids to create the 
bubbles. There was a distribution of sizes that will follow from this methods as bubbles can 
coalesce into larger bubbles over time.  
Visual analysis was done for confirmation of microbubbles production as the when bubbles were 
in the micron size range the center will have different light diffraction thus brightfield microscopy 
can be used to heuristically determine if there were microbubbles present.  From Figure 3.7 it 
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clearly shows micron-sized bubbles with a spherical morphology. For both control lipid and Pro-
Bexarotene, larger bubbles were more prominent in the graphic due to 20X magnification. In 
comparing to literature, the images were similar in morphology. 
  
Figure 3.7 Bright field images of microbubbles under 20X magnification. (A) Displays the 
HSPC control microbubbles. (B) Shows the Pro-Bexarotene microbubbles with both images 
using a 20 µm scale bar. Optical diffraction causes bubbles to have halos larger than the actual 
object.  
Figure 3.8 shows the size measurements for the bubbles produced via the sonication method where 
Pro-Bexarotene showed an average of 1.5 µm and the control bubbles were at 2.5 µm. 
Additionally, the concentration of number of bubbles in solution can be quantified from Accusizer 




Figure 3.8 Microbubble size distributions using an Accusizer displays the number average for 
species scaling from 0.5 µm-8 µm. The average sizes for the PBMB and control were 1.5 and 2.5 
µm respectively. 
Bexarotene was 6.86 ∗ 10 . Another characteristic of microbubbles that can be useful in 
identification was the inherent acoustical attenuation from ultrasound imaging. In Chapter 3.5 
there were experiments conducted to confirm the presence and the enhancement ultrasound 
imaging contrast. 
Modeling 
Mathematical modeling of the bubble dynamics can provide a robust estimation of stability in 
solution. The model used for this analysis was written by Sakar et al. and it combines a model 
previously developed by Epstein-Plesset with mass transport to predict bubble lifetime. The basis 
of the Epstein model was Laplace overpressure which will occur at curved surfaces. In 
microbubbles, there is gas that is surrounded by a surfactant. The surfactant has its surface tension 
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which will hold the gas inside of the assembly creating the overpressure. The smaller the bubble 
the higher the Laplace pressure and it will eventually drive the dissolution of the bubble even in 
highly saturated liquids. This was the basis for introducing many of the fluorinated heavy gasses 
currently used in clinical microbubbles to extend imaging times and improved stability. The 
fluorinated gases have a much lower diffusion coefficient in solution and will not easily dissolve 
in solution. This leads to longer shelf lives because the interior gas is not favored break across the 
membrane of the lipid thus allowing for the bubbles survive longer in solution. The model starts 
with a basic diffusion problem of a spherical object and gas transport through a shell. Equations 
5,6,7 show the set of coupled dimensionless differential equations that model growth and 
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These equations were nondimensionalized and as such A and F were the dimensionless 
concentrations of air and fluorinated gas. R was dimensionless radius in relation to the initial 




























Table 3.3 shows the initial conditions used to run the MATLAB simulation where X  was the mole 
fraction of the OFP in the bubble and in this case, and it was chosen to be 1. This would assume 
an ideal scenario where OFP was the only gas entrapped. R(0) assumed that relatively the bubble 
starts at no growth, A(0), and F(0) was the initial amount of air and OFP in the bubble.  
Table 3.3: Initial conditions for simulation 
Initial Conditions 
R(0) = 1 A(0) = (1 − X )(R + γR0
2
) F(0) = X (R + γR0
2
) 
Values of the constants were taken directly from Sakar et al. after confirmation the model covered 
OFP based lipid bubbles and values for constants such as diffusivity, convective transport, and 
Ostwald’s coefficient will remain the same for OFP and air in solution [30-32]. Factors that were 
determined experimentally were surface tension (γ) and initial radius (R ). The computations were 
done through MATLAB using a stiff ODE solver. The code was provided in Appendix A. Using 
this model, estimation of stability and size of the microbubbles can be predicted. Figure 3.9 shows 
the overall surface tension measurements and stability profiles for Pro-Bexarotene and HSPC. 
Measurements were done through a surface contact goniometer. The addition of lipids and other 
surfactants was supposed to lower water’s surface tension [32]. As seen in Figure 3.9A the surface 
tension decreases drastically when HSPC and Pro-Bexarotene were added. This, in turn, can be 
inputted into the model for estimation of bubble profile in Figure 3.9B. The HSPC bubble was 
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estimated stable for 510 seconds and PBMB was estimated to be 771 seconds. The values of the 



























Figure 3.9 (A) Surface tension measurements of HSPC and PB in solution through contact angle 
measurements in a goniometer. The addition of lipids showed a clear decrease in surface tension. 
(B) Estimated growth and dissolution of microbubbles based on surface tension values from the 
model. With a time of dissolution for HSPC and PBMB to be 510 and 711 seconds respectively.  
3.2 OPTIMIZATION OF MICROBUBBLE ULTRASOUND EXPOSURE 
Ultrasound is defined as high-frequency sound waves (>20kHz) usually 3MHz and up for medical 
imaging. For this work, ultrasound was used to destroy microbubbles. Therefore, a lower 
frequency was used at 1 MHz, which was within the range of destructive ultrasound (<2 MHz). 
Testing of ultrasound exposure needed to be optimized based on the inherent properties of 
ultrasound to input energy into a closed system. This, in turn, will cause temperature changes in 
confined environments such as the in vitro testing of this system. When designing the system 





Figure 3.10 (A) Cartoon diagram of the exposure to each well including inversion. (B) 24 well 
plate layout to isolate each well shown in pink. (C) 96 well plate layout with 9 well used for each 
treatment as it was the maximum number of wells completely covered by the sonication head. 
The first step of optimization for ultrasound exposure started with the determining a proper length 
of exposure as this would be used to simulate in vitro testing. The length of the well was found to 
be 1 inch and on top of that, there would be a PCR film applied to the top of the 24 well plate to 
seal the plate. Multiple types of plates were utilized for experimentation starting with large 6 well 
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plate. These were designated for larger cell populations testing such as DNA damage assay. 
Followed by 24 and 96 well plates for smaller scale cell viability testing via MTT assay. Water 
was used as a substitute for cell culture media and the well were irradiated for varying times. 
Shown in Table 3.4 below the time was scaled from 0 to 3 minutes using 30-second intervals. It 
was found that the direct ultrasound was focused on the device near the center of the sound horn 
and as such, it was utilized as the focal point for the wells. Each of the times shows no melting, 
but at the time of exposure went beyond 2.5 minutes the melting became present. This gives the 
maximal time of exposure for ultrasound in a 24 well plate.  
Table 3.4: Visual results of melting assessment for ultrasound exposure in plates depending on 
the time of exposure. 









3.3 MICROBUBBLE DISSOLUTION 
The experiment done was as described in Chapter 2.13. Figure 3.11 shows the results of the 






































Figure 3.11 Dissolution study of HSPC microbubbles under varying ultrasound exposure times. 
(A) DLS intensity data exposure times ranging from 0 to 5 minutes using 1-minute intervals. 
Exposure shows the production of multiple peaks as exposure increases. (B) Peak averages plotted 
with time in addition to the regression model. (C) Regression model for one phase decay showing 
half size reduction at 0.8058-minute exposure. 
The data shown in Figure 3.11A displays a decaying intensity average for hydrodynamic diameter 
and widening of the distribution as time of exposure increased. This was fitted to an exponential 
decay model to find a half-life for bubble size which was 0.8058 minutes shown in Figures 
3.11B/C. Analyzing this experiment confirms the main conclusion that the ultrasound exposure 
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from the machine does, in fact, cause the microbubbles to break. The specific time required to 
microbubbles to break happens instantly looking at Figure 3.11A with size reduction at 1 minute 
of exposure, so the time optimal for enhancement of drug delivery will be experimented for in the 
following sections. 
3.4 IN VITRO OPTIMIZATION 
With the confirmation that ultrasound exposure from the machine will cause the microbubbles to 
break, the next logical step was to optimize an in vitro experiment. This was done using two main 
experimental techniques cell culture and an MTT assay. Starting with an initial experiment to test 
for the effectiveness of the Pro-Bexarotene as a therapeutic agent, C32 cells were cultured on 96 
well plates at standard conditions and allowed to grow overnight in the incubator. After which, the 
cells were treated with the described application where cell media was replaced with new media 
spiked at a certain concentration of a treatment, here two times Bexarotene’s estimated standard 
IC50 was chosen. The IC50 of Bexarotene was estimated to be 50 µM in the C32 cell line, and as 
such, all the wells were concentrated similarly including the controls and incubated for 48 hours 
checking daily to monitor for contamination [33]. Figure 3.12 displays the results for the MTT 
assay 48 hours post-treatment, which shows that all forms of the prodrug will reduce the cell 
viability of the C32 cells. In comparison, to its lipid controls, there was a high level of significance. 
As would be expected Bexarotene is an RXR agonist and the C32 cell line is a melanoma where 
the RXR pathway is open [34]. Misra et al. showed that Pro-Bexarotene was cleavable in an 
environment with phospholipase A or low pH, and cancer cells were shown known exhibit lower 
pH microenvironments [15]. Additionally, Figure 3.12 confirmed that the control lipid was indeed 




Figure 3.12 MTT analysis of controls and Pro-Bexarotene using C32 cell lines with a concentration 
of trials at 2 times the estimated IC50 value for Bexarotene in C32 cells. The experiments were 
performed in triplicates, and statistical analysis was done using a one-way ANOVA where the 
lipid control was taken as the control and compared with other formulations. The cell viability of 
the treatments was plotted as mean ± standard deviation, and * = p<0.05, ** = p<0.01, *** = 
p<0.001 and **** = p<0.0001. 
After confirmation that the prodrug was indeed an effective mean of therapy cell-based assays 
were developed. Using the standard arrays patterning shown in Figure 3.10. 
To increase the number of replicates the plate set for the 96 well plate was used. Here there would 
be 9 replicates allowing for a higher chance of getting reproducible results. The time of exposure 
was 2 minutes less than the approximate time of melting at 2.5 minutes. The optimizations began 
using the maximal melting point time in conjunction with a patterned cell array to create triplicate 
experiments in an isolated environment. The concentration of the wells was reduced to 5 µM to 
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better ascertain information on ultrasound effectiveness. The results of the experiment can be seen 
in Figure 3.13. A two-way ANOVA test was performed using the following hypotheses H0: 
Ultrasound has no effect on cell viability/drug uptake, H0,1: Drug formulation had no effect cell 
viability/uptake, and H0,2: Ultrasound and formulation interactions had no effect on cell 
viability/drug uptake. Details from the ANOVA analysis conclude that H0 was rejected while the 
rest (H0,1 and H0,2) were accepted. Concluding that ultrasound was an effective enhancer of drug 
incorporation. A hallmark of the MTT assay was the comparison of treatments to similarly tested 
controls, and it was where the percentage of cell viability was calculated. This would indicate that 










Figure 3.13 Ultrasound effectiveness testing using MTT. Various formulations were used to 
investigate the effectiveness of ultrasound in enhancing uptake of drug molecules using 5µM 
concentrations for each well. The experiments were performed in nine replicates, and statistical 
analysis was done using a two-way ANOVA where the ultrasound was found to be significant. 
The cell viability of the treatments was plotted as mean ± standard deviation, and * = p<0.05, ** 
= p<0.01, *** = p<0.001 and **** = p<0.0001. 
The next step involves optimizing the assay to determine two main factors a minimum 
concentration of microbubbles that will elicit the desired reduction of cell viability when 
ultrasound was applied, and a time of exposure that will work in conjunction with microbubbles. 
To begin the optimization the 96 well plate in Figure 3.13 was conducted again with a completely 
isolated set up with each individual plate being tested as a single treatment. The data was displayed 
in Figure 3.14. This data did not allow for any definitive conclusion only conjecture that isolation 
may not pay as much of a role when treating, and this could make intuitive sense the space between 
the wells was air, not a medium that will transfer ultrasonic energy efficiently. Additionally, the 
presence of 9 replicants can cause inherent variability in this system. As the ultrasound machine 
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was a consumer product and had a clear center beam when water was placed on top of the head. 
This could, in turn, irradiated the wells unevenly no matter how thorough application. So, from 
this information, the 24 well approach was taken while each experiment will only produce a single 
triplicate the center beam can be located and focused to cover the entire well.  
 
Figure 3.14 Second attempt at to analyze ultrasound effectiveness using 96 well plate to closely 
examine the effect of ultrasound exposure using 5 µM concentrations for each well. The 
experiments were performed in nine replicates, and statistical analysis was done using a two-way 
ANOVA. No results were found to be significant and there was great variability in recorded 




Figure 3.15 Plate optimization study using a 24 well plate for in vitro testing. All aspects of the 
experiment were kept the same including the concentration of 5 µM and time of exposure of two 
minutes per well. The experiments were performed in three replicates, and statistical analysis was 
done using a two-way ANOVA. The results showed a two-star significance with ultrasound in 
PBMB. The cell viability of the treatments was plotted as mean ± standard deviation, and * = 
p<0.05, ** = p<0.01, *** = p<0.001 and **** = p<0.0001. 
Another experiment utilizing PBMB and PBP was done again in a similar method here instead of 
using the 96 well plate the patterned plated for a 24 well plate shown in Figure 3.10C. The 
concentrations in each well were kept at 5 µM with a new variable where the MTT assay was 
performed after 24 hours. Additionally, changes were made to this experiment including changing 
the type of media used for delivering the drug from EMEM with phenol red to a phenol red-free 
DMEM. This was done so there could be an analysis of the media with UV-Vis spectroscopy. As 
Bexarotene is a molecule associated with a UV signature and from literature and experiments there 
was a peak at λmax=277 nm. Samples were grown according to Chapter 2.11 using proper seeding 
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density and EMEM media. After 24 hours the plates were ready for testing the media was replaced 
and concentrated with 5 µM of Pro-Bexarotene microbubbles, or particles with the inclusion of a 
control. Samples were sealed and exposed to ultrasound as described before with a two-minute 
ultrasound exposure. Post-exposure the samples the plastic film was removed, and the samples 
were placed back into the incubator for 6 hours. This time point was chosen as waiting a 24 hour 
as with the previous experiments would be a complete change of medium where it could influence 
the cell growth due to media contents. After 6 hours the DMEM was and kept refrigerated for 
testing, and the cells were washed with DPBS and new EMEM was replaced at a volume suggested 
for cell culture in 24 well plates.  All other aspects were kept the same such as ultrasound exposure 
intensity and the time of exposure.  
Figure 3.16A shows the calibration curve that was used to estimate the concentration of the treated 
samples this was based on dissolving Pro-Bexarotene to create a sample of 121.1 µM concentration 
and serially diluting them 1:2 in phenol-free DMEM. Followed by reading the UV-Vis spectra of 
each sample using its local maximum from 230 to 300 nm as the absorbance value. Serial dilutions 
began at the 121.1 µM sample, and it was diluted until the absorbance peak was below 1.000 where 
the Beer-Lambert Law was valid. This was found to be between 30.275-1.892 µM as shown in 
Figure 3.16A. This was then plotted according to the Beer-Lambert Law to produce a linear model 
that will relate the concentration of Pro-Bexarotene to the absorbance of the sample. Figure 3.16B 
shows the UV spectra from 270-285 nm for the four tested samples. With this data and the model 
from Figure 3.16A, the concentration of each well can be calculated. The results suggest that the 
uptake of the drug when ultrasound was applied which in turn increases the metabolism of the drug 
explaining the difference irradiated and the control. Figure 3.16C shows the concentration of for 
each of the samples after the 6 hours of incubation a two-way ANOVA test was done here where 
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the rejected hypothesis was that ultrasound had no effect on concentration. Effectively confirming 
and quantifying a major part of this work. From calculations, the relative percentage of the drug 
uptaken in comparison to the initial concentration for each sample was shown in Table 3.5.  
Table 3.5: Percent of uptake for drug depending on formulation and ultrasound exposure based on 
initial concertation. 
Ultrasound Treatment Formulation Percent of Uptake 
US+ PBMB 51.93 
 PBP 55.08 
US- PBMB 47.74 
 PBP 40.40 
 
Additionally, there was an observation on how the bubble formulation was having a higher value 
of uptake and metabolism than in the control set as can be seen in Figure 3.16D. A possible theory 
for this can be interactions with the bubbles depositing onto the monolayer of cells, and due to the 
inherent instability of the bubbles they will break apart and some may have a similar effect of the 
microjet membrane disruption and deposition [11]. That would encourage more drug molecules to 
enter the cells. Figure 3.16D shows the cell viability data from there a two-way ANOVA was 
performed showing the effectiveness of ultrasound with a two-star significance. The other point to 
note here was that in this scenario the decrease was lower but not as significant as the previous 
MTT data from Figure 3.13. The average cell viability was for PBMB, US+ was 79% as opposed 












Figure 3.16 Concentration analysis of drug delivery. (A) Calibration curve of Pro-Bexarotene 
serially diluted in Phenol-Free DMEM using the UV absorbance spectra peak at λmax=277nm. (B) 
Absorbance peaks of each treatment between 270<λ<280 showing the peak reduction based on 
ultrasound exposure. (C) Concentration calculations of each treatment after testing depending on 
the max absorbance experiments were done in triplicates. Followed by a statistical analysis was 
done using a two-way ANOVA. Where ultrasound was shown to have a two-star significance in 
reduction of concentration. (D) Cell viability data associated with the experiment using the same 
wells concentration was calculated from, and statistical analysis from a two-way ANOVA finds 
that ultrasound reduced cell viability to a two-star significance. The concentration and the cell 
viability of treatments was plotted as mean ± standard deviation, and * = p<0.05, ** = p<0.01, *** 
= p<0.001 and **** = p<0.0001. 
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Following confirmation of the of drug delivery, the next step was to optimize the concentration. 
In the previous experiments the concentration was kept constant at 5 µM, but to see the complete 
effectiveness of this system, an array of concentrations should be tested. The experiment was like 
before with the expectation that time will also be further optimized, and the only aspect needed to 
be tested was the bursting of the bubble with the varying concentration. As such the sonication 
time was reduced to 40 seconds for all the trials. Additionally, particles were not sonicated as the 
point of this experiment was to see if a microbubble system with ultrasound can outperform a 
micellar drug delivery system. Figure 3.17A shows the initial test done with 5 µM and 10 µM 
concentrations, the data showed no significance in cell viability loss between the two and the 
assembly. As such additionally concentration were used ranging from 1.25, 2.5, 5, 10, and 20 µM. 
The data was summarized in Figure 3.17B it shows the behavior that would be expected as the 
concertation decreased the cell viability began to increase for both the bubble and particle. The 
key aspect to note was that when a concentration of 1.25 µM was reached the particles where not 
metabolizing the prodrug leading to the increased cell viability, and in comparison, the bubble 
form decreased cell viability to below 60 % on par with the data from 2.5 µM. The point of the 
optimization was to find to a concentration where there will be a significant difference between 
the bubble and the particle, and in Figure 3.17B the clear point was seen at 1.25 µM where it shows 
a four-star significance in comparison. An experimental IC50 for C32 cells can be estimated from 




Figure 3.17 Concentration optimization of the assay. (A) Shows an initial study using a 40 second 
time of exposure and varying concentration of the same experiment. No reliable conclusion could 
be drawn from this experiment and led to the next optimization. (B) Concentration varied with a 
cell viability analysis using the same time of exposure with the addition of more samples. Analysis 
from the two-way ANOVA show three-star significance on both factors and the interaction. The 
key conclusion was the three-star significance seen between the bubble and particle in a 
comparisons test. Allowing for an optimized concentration. The concentration and the cell viability 
of treatments was plotted as mean ± standard deviation, and * = p<0.05, ** = p<0.01, *** = 
p<0.001 and **** = p<0.0001. 
After finding the optimal concentration now the time of exposure must be optimized. 
Experimentally this was done by plating a 24 well plate in triplicates as shown before in Figure 
3.10. Now the optimized concentration of 1.25 µM was used in each of the wells. Here the particles 
were not tested as they would remain constant through the experiment. The wells were then 
irradiated with ultrasound for a specific amount of time. After exposure, the protocol was kept the 
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same with the removal of the media and replacing with fresh media followed by an MTT assay 
after 24 hours. The data shows from a one-way ANOVA and multiple comparisons there was a 
four-star significance from the control and 1.5 minutes. This provided the optimized time for 
exposure. Increasing the time of exposure decreased the cell viability at each time point and in 
comparison, to Figure 3.17B there was a similar cell viability for the 40-second exposure.  
 
Figure 3.18 Ultrasound exposure time of exposure optimization. Cells were tested with the 
optimized concentration of 1.25 µM of bubbles at different times of exposure. The 1.5 minutes of 
exposure allowed for a four-star significance, and it was chosen as the optimized time. 
Experiments were done in triplicates followed by a one-way ANOVA using the zero time as the 
control. The concentration and the cell viability of treatments was plotted as mean ± standard 
deviation, and * = p<0.05, ** = p<0.01, *** = p<0.001 and **** = p<0.0001. 
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The final step of optimization was the analysis of this therapy using flow cytometry. Bexarotene 
mode of action is to induce apoptosis in cells that contain the specific RXR receptors [15]. This 
can be assessed through DNA damage which can be quantified by flow cytometry. Where 
propidium iodide will bind to breaking DNA that would be present in apoptotic cell causing a left 
shift in the red fluorescent channel. The experimental protocol was set up, so the optimized 
parameter of concentration and time of exposure were used. The specific protocol can be seen in 
Chapter 2.15 the main aspect was 6 well plates were grown then treated like the optimized 
experiment. The 6 well plate was used to scale for the larger number of cells but does not have any 
issues with melting and uneven exposure due to the similar size of the well and ultrasound machine 
head. The results of the experiments can be summarized in Figure 3.19 where it shows a clear left 
shift of the populations when bubbles were used in conjunction with ultrasound. This would 







Figure 3.19 DNA damage results from in vitro testing. (A) Flow cytometry data testing method of 
cell death for controls experiments showing the overall lower number of events captured as would 
be expected. (B) Data showing that ultrasound in addition to bubbles will cause a leftward shift in 
the peak indicative of DNA fragmentation.  
3.5 ULTRASOUND IMAGING 
Ultrasound imaging was that last confirmatory tool that used to characterize these microbubbles. 
As described in the introduction ultrasound will interact with materials and the differences in the 
reflected sound waves will be formed into images. The varying acoustical attenuation of tissue 
causes the ability to discern different parts from each other. Microbubbles were supposed to show 
an increased contrast in ultrasound imaging [35]. As such an experiment was developed to examine 
if the Pro-Bexarotene microbubbles enhance ultrasound contrast. The phantom and ultrasound 
imaging system were described in Chapter 2.15. The results are shown in Figure 3.20 where from 




Figure 3.20 Ultrasound imaging using various solutions in a thin-walled phantom with a 3.5 MHz 
transducer and Siemens on-board image processor. (A) Water filled phantom showing a base for 
imaging quantifications. (B) Control microbubbles made of soy lecithin at a concentration of 1 . 
(C) Pro-Bexarotene microbubbles at a concentration of 1  showing a higher contrast in 
comparison to water and the control. 
Further analyzing the images using ImageJ showed that the brightness increased significantly for 
the PBMB sample [36]. Shown in Figure 3.21 the increase in the 150-pixel count for PBMB was 













Figure 3.21 Ultrasound imaging quantification using ImageJ using a set area of 435x365 pixels for 
each image. Utilizing the histogram function on the ultrasound images from Figure 3.20 analysis 





CONCLUSION AND FUTURE DIRECTIONS 
4.1 CONCLUSION 
This work encompassed development and characterization of a novel microbubble drug delivery 
system. It began with initial research and calculations in lipid packing and microbubble formation. 
Following with multiple optimizations to develop a protocol for creating microbubbles via 
sonication for Pro-Bexarotene and soy lecithin. These microbubbles were then used and developed 
into an in vitro assay that quantified their effectiveness in conjunction with therapeutic ultrasound.  
The main points of this work are summarized: 
 Packing parameter calculations and modeling stated that Pro-Bexarotene will self-
assemble spherically and be stable in solution for 711 seconds.  
 Consumer grade ultrasound equipment used in the testing work well to break apart 
microbubbles.  
 Pro-Bexarotene was shown to be an effective therapeutic for C32 cells. Followed by 
confirming and quantifying that ultrasound will enhance the uptake/metabolism of Pro-
Bexarotene. Optimization experiments were conducted to find an optimal concentration of 
1.25 µM and an exposure time of 1.5 minutes for a 24 well plate. This was ended with a 
study assessing the Pro-Bexarotene microbubbles method of action which was found to 
induce apoptosis. 
 Ultrasound imaging showed increased contrast with Pro-Bexarotene microbubbles in 




4.2 FUTURE DIRECTIONS 
This work addresses a single facet of the potential for ultrasound enhanced drug delivery. There 
are a variety of applications for this technology. As it uses a consumer system to locally enhance 
drug uptake. A drug-related example is localized pain medication. Due to the highly addictive 
nature of opioids, when they are given post-surgery there is a chance for dependency. This system 
modified, can be alternative as it’s has shown that you can reduce the concentration and have a 
similar effect on cell viability. Studies would need to be done, but it offers a new way to approach 
for applications. Other uses for consumers could be applications for skin care such as skin elasticity 
and hair rejuvenation. All these examples would require re-engineering of the system but are 
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APPENDIX A: MATLAB CODE 
A.1 PACKING PARAMETER CALCULATIONS 
% Packing Parameter Calculations 
  
% Equations based on Micelles, Vesicles, and Microemulsions by Mitchel and 
% Ninham published in J. Chem. SOC., Faraday Trans. 2, 1981,77, 601-629  
  
%-------------------------------------------------------------------------- 
% HSPC Estimation 
  
% Ellipsoid geometry assumed for surfactant head and truncated cone is used 
% for tail volume. All values are in Angstroms(A). 
  
% Head surface area based on Avogadro estimates 
a=2.6676/2;       % Shortest radius at the center of the ellipsoid 
b=7.274/2;        % Maximum length of the ellipsoid 
c=5.84787/2;      % Normal length to maximum 
  
p=1.6075;         % Factor chosen from literature [K. Thomsen] 
% Surface area of an ellipsoid from Elementary Approximations to the Area  
% of N-Dimensional Ellipsoids by Klamskin 
ao=4*pi()*(((a^p)*(b^p)+(a^p)*(c^p)+(b^p)*(c^p))/3)^(1/p); 
  
% Tail volume [truncated cone] 
r2=7.25555/2;     % Inner radius 
r1=13.9808/2;     % Larger radius 
h=16.5081;        % Height 
V=(1/3)*pi()*((r1^2)+(r1*r2)+(r2^2))*h; 
  
% Tail length 
le=17.6084; 
  




% Pro-Bexarotene Estimation 
  
% Ellipsoid geometry assumed for surfactant head and cylinder is used 
% for tail volume. All values are in Angstroms(A). 
  
% Head surface area based on Avogadro estimates 
a=2.39427+0.6/2;  % Shortest radius at the center of the ellipsoid 
b=16.209/2;  % Maximum length of the ellipsoid 
c=7.124/2;        % Normal length to maximum 
  
p=1.6075;         % Factor chosen from literature [K. Thomsen] 
% Surface area of an ellipsoid from Elementary Approximations to the Area  





% Tail volume [half cylinder estimated using Autodesk Inventor] 
V=969.573 
  
% Tail length 
le=11.322 
  
% Packing parameter 
PackParProBexN=V/(ao*le) 
 
A.2 GROWTH AND DISSOLUTION MODEL 
% Growth and Dissolution Model of OFP Microbubbles 
  
% Equations and analytical solutions are taken from the paper  
% Growth and dissolution of an encapsulated contrast microbubble: effects  
% of encapsulation permeability by Sarkar, Katiyar, Jain published in 




% Constant definitions  
r0=1.25*(10^-6);                 % Initial Radius of bubble [m] 
patm=101325;                     % Atmospheric pressure [Pa] 
ka=2.05*(10^-9);                 % Coefficient of diffusivity of air through 
liquid medium [m^2/s] 
kf=7.45*(10^-10);                % Coefficient of diffusivity of OFP through 
liquid medium [m^2/s] 
hf=1.2*(10^-6);                  % Permeability of air through membrane [m/s] 
ha=2.857*(10^-5);                % Permeability of OFP through membrane [m/s] 
gam=0.025;                       % Surface Tension [kg/s^2] 
lam=ka/kf;                       % Ratio of air to OFP diffusivity 
La=1.71*(10^-2);                 % Ostwald ripening coefficient of air 
f=0.9;                           % Interface saturation level 
ala=ka/(ha*r0);                  % Dimensionless air diffusivity number 
Lf=5.2*(10^-4);                  % Ostwald ripening coefficient of OFP 
dlga=(2*gam)/(patm*r0);          % Dimensionless surface tension 
alf= kf/(hf*r0);                 % Dimensionless OFP diffusivity number 
  





% Empty matrix is created to hold values when function is called 
drdt=zeros(3,1); 
  









% Creates a function to run the growth and dissolution model  
function [t,x] = OdeSolver(startTime,endTime,numberOfDataPoints,initCond) 
  
% basic syntax for ode solver 
[t,x] = 
ode15s(@GnDmodel,linspace(startTime,endTime,numberOfDataPoints),initCond); 
     
end 
 
% Simulation of growth and dissolution of Pro-Bexarotene microbubbles using 
% data collect 
function RunOdeSolver 
    % Constants 
    dgla=(2*0.025)/(101325*(1.25*10^-6)); % Dimensionless surface tension 
    kf=7.45*(10^-10);                     % Diffusivity of air 
    Xf=1;                                 % OFP mole fraction 
    ro=1.25*10^-6;                        % Initial Bubble diameter [m] 
     
    % Total time of simulation [dimensionless] 
    startTime = 0.001; 
    endTime = 10^6; 
  
    % Selection of data points 
    numberOfDataPoints = 100001; 
         
    % Setting initial conditions 
    Ro=1; 
    Ao=(1-Xf)*((Ro^3)+((Ro^2)*dgla)); 
    Fo=Xf*((Ro^3)+((Ro^2)*dgla)); 
    initCond = [Fo,Ao,Ro]; 
       
    % Running of simulation        
    [t,x] = OdeSolver(startTime,endTime,numberOfDataPoints,[initCond]); 
    % Redimenionalizing time into seconds 
    t=(t*((ro)^2))/kf; 
    % Plotting 
    semilogx(t,x(:,3),'b'); 
    axis([.001 10^4 0 3]) 
    xlabel('time[s]') 
    ylabel('Relative Radius')    
    
end 
 
 
 
 
